Owl Therapeutics
Owl Therapeutics is dedicated to developing neurotherapeutics aimed at enhancing the function of microglia, which are crucial for clearing brain cell debris and inflammation resulting from brain injuries and diseases. The company focuses on providing hope for patients suffering from traumatic brain injury (TBI), Alzheimer's disease (AD), and related conditions.
Owl Therapeutics
200 E Grayson St Ste 101, San Antonio, TX 78215, USA
Owl Therapeutics is currently seeking investment
Owl Therapeutics is seeking a investment in the range of
What We Do
OWL-1023-AI
A best-in-class monoclonal antibody engineered to clear brain cell debris, a process critical for neurological recovery.
OWL-4130-AI
A best-in-class fusion protein engineered to clear inflammation, potentially reducing secondary degeneration and enhancing recovery outcomes.
OWL-1410-AI
Highly selective small molecule to protect and restore microglia and other brain cells by protecting mitochondria-the 'powerhouses of the cell'.
Application Area
Biologics
Key People
William Haskins
Co-Founder & CEO
Franklin Okumu
Co-Founder & CTO
Co-Founder & Chair of Scientific Advisory Board
Henry Lowman, PhD
Co-Founder & Technical Advisor
Todd Kilbaugh
Co-Founder & Clinical Advisor
News & Updates
Owl Therapeutics will present a novel approach to unlocking the traumatic brain injury market.
Owl Therapeutics will present the latest data at the RESI JPM San Francisco 2024 Conference.
Owl Therapeutics has entered a strategic clinical collaboration with Abliva to advance NeuroSTAT® (OWL-1410) for traumatic brain injury.
Abliva and Owl Therapeutics have entered into a licensing and collaboration agreement for NeuroSTAT® in traumatic brain injury.